SAN DIEGO, April 26, 2021 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted cellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, today announced the appointment of William Sandborn, M.D. as Chief Medical Officer. Dr. Sandborn is a world-renown award-winning key opinion leader, inflammatory disease clinician, and scientific co-founder of multiple biotechnology companies.
